Caladrius Biosciences, Inc. (CLBS)
(Delayed Data from NSDQ)
$2.94 USD
+0.09 (2.98%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.97 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.94 USD
+0.09 (2.98%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.97 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
The Keys to Successful Timing the Markets - August 15, 2019
by Zacks Equity Research
Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?
Top Ranked Momentum Stocks to Buy for August 5th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 5th
Top Ranked Momentum Stocks to Buy for July 25th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 25th
What Makes Caladrius Biosciences (CLBS) a New Buy Stock
by Zacks Equity Research
Caladrius Biosciences (CLBS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock
by Zacks Equity Research
Agios' (AGIO) loss tops estimates in Q3. Its precision medicine Tibsovo's performance in the very first quarter after approval in July leads to a significant year-over-year revenue growth.
Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up
by Zacks Equity Research
Acorda's (ACOR) Q3 rides high on earnings and revenue beat amid a strong generic competition for its MS drug Ampyra and the expected launch of its Parkinson's candidate, Inbrija.
AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally
by Zacks Equity Research
AcelRx (ACRX) earns majority votes from an FDA advisory committee, which recommends approval of Dsuvia for treating moderate-to-severe acute pain in adult patients.
bluebird's MAA for LentiGlobin Gene Therapy Accepted by EMA
by Zacks Equity Research
bluebird's marketing authorization application (MAA) for its experimental gene therapy, LentiGlobin, was accepted by the regulatory body in Europe.
Alnylam Files Clinical Trial Application for ALN-AAT02 in UK
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.
VistaGen Up on Fast Track Designation to Pain Candidate
by Zacks Equity Research
VistaGen (VTGN) Fast Track designation for its pipeline candidate, AV-101, for treating neuropathic pain.
Paratek Pharmaceuticals (PRTK) in Focus: Stock Moves 8.7% Higher
by Zacks Equity Research
Paratek Pharmaceuticals (PRTK) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Caladrius Biosciences (CLBS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Caladrius Biosciences, Inc. (CLBS).
Is Caladrius Biosciences (CLBS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CLBS) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
Why These 4 Biotech Stocks May Not Lose Momentum Soon
by Zacks Equity Research
The biotech industry has shown strength so far this year. The momentum is likely to continue for some time, it's a good idea to pick a few stocks that are unlikely to lose their momentum soon.